Voyager Therapeutics (NASDAQ:VYGR) CEO Sells $44,547.57 in Stock

Key Points

• Voyager CEO Alfred Sandrock sold 11,511 shares on April 2 at an average price of $3.87 for a total of $44,547.57, executed under a pre-arranged Rule 10b5-1 plan and leaving him with 472,549 shares (a 2.38% ownership decrease).
• Those April sales follow two earlier transactions (Feb. 24: 14,197 shares; Feb. 10: 12,192 shares), meaning he has sold a total of 37,900 shares year-to-date for roughly $144,440.
• For context, VYGR is trading near $3.96 with a market cap of about $236M, recent quarterly revenue that beat estimates but negative EPS, and an average analyst target of $16.50 (consensus: Moderate Buy).

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) CEO Alfred Sandrock sold 11,511 shares of the business's stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total transaction of $44,547.57. Following the transaction, the chief executive officer owned 472,549 shares in the company, valued at approximately $1,828,764.63. This represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alfred Sandrock also recently made the following trade(s):

• On Tuesday, February 24th, Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock. The stock was sold at an average price of $3.79, for a total value of $53,806.63.
• On Tuesday, February 10th, Alfred Sandrock sold 12,192 shares of Voyager Therapeutics stock. The shares were sold at an average price of $3.78, for a total value of $46,085.76.

Voyager Therapeutics Price Performance

NASDAQ VYGR remained flat at $3.96 on Friday. The company's stock had a trading volume of 462,509 shares, compared to its average volume of 965,122. The firm has a 50-day simple moving average of $3.92 and a 200 day simple moving average of $4.19. Voyager Therapeutics, Inc. has a 1 year low of $2.64 and a 1 year high of $5.55. The company has a market capitalization of $236.02 million, a P/E ratio of -1.95 and a beta of 1.38.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.08. The company had revenue of $13.46 million for the quarter, compared to analyst estimates of $10.49 million. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%. On average, research analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VYGR. Wexford Capital LP acquired a new stake in Voyager Therapeutics in the 3rd quarter worth approximately $42,000. ProShare Advisors LLC bought a new position in shares of Voyager Therapeutics in the fourth quarter valued at approximately $44,000. CIBC Asset Management Inc acquired a new stake in shares of Voyager Therapeutics in the fourth quarter worth $45,000. Coldstream Capital Management Inc. acquired a new position in shares of Voyager Therapeutics during the third quarter valued at about $55,000. Finally, EHP Funds Inc. acquired a new position in shares of Voyager Therapeutics during the third quarter valued at about $58,000. 48.03% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on VYGR. Wall Street Zen upgraded shares of Voyager Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, March 14th. HC Wainwright restated a "buy" rating and set a $25.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, March 17th. Finally, Truist Financial raised shares of Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Voyager Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $16.50.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.